DARZALEX FASPRO® dosing schedules for adult patients who are relapsed or refractory*

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) monotherapy (4-week cycle) has the same dosing schedule as DARZALEX® (daratumumab). DARZALEX FASPRO® is a ready-to-use, single-use vial, which includes a fixed dose and no weight-based calculations.1,2

Dosing frequency decreases over time1
DARZALEX FASPRO® monotherapy dosing regimen in patients with >3 prior therapies
Continue DARZALEX FASPRO® once every 4 weeks until disease progression or unacceptable toxicity1
Administer medications before and after administration of DARZALEX FASPRO® to minimize systemic ARRs.1

First dose of the every-2-week dosing schedule is given at Week 9.

First dose of the every-4-week dosing schedule is given at Week 25.

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.

ARRs=administration-related reactions.